Composite of breviscapinum and panax notoginseng saponins Rg1 for treating pulmonary fibrosis and application thereof

Abstract

The invention provides a composite of breviscapinum and panax notoginseng saponins Rg1 for treating pulmonary fibrosis, wherein the weight ratio of the breviscapinum to the panax notoginseng saponins Rg1 is 2-5:1-2. The invention also provides application of the composite in the preparation of a medicament for treating the pulmonary fibrosis. The composite of the breviscapinum and the panax notoginseng saponins Rg1 is formulated in a certain proportion and has the advantages of favorable pulmonary fibrosis resistance, remarkable effect and little side effects. Raw materials of the composite are easily obtained and can be prepared in various common dosage forms, such as tablets, capsules, injections and the like, through a conventional method with simple preparation method. The pharmacological action of the composite is obvious; in vitro, the composite can inhibit the activity of human embryonic lung fibroblasts and has favorable dosage dependence; and in vivo, the composite can lower the lung coefficient of a mouse with the pulmonary fibrosis and the content of hydroxyproline of lung tissues and also relieve the alveolitis of the mouse with the pulmonary fibrosis and reduce the degree of the pulmonary fibrosis.

Description

technical field [0001] The invention relates to a composition for treating pulmonary interstitial fibrosis, in particular to a composition composed of breviscapine and notoginsenoside Rg1, and the application of the composition in the preparation of medicines. Background technique [0002] Pulmonary interstitial fibrosis is a pulmonary interstitial lesion caused by different etiologies or unknown causes. Its pathological features are early alveolar structural destruction and diffuse alveolitis, followed by excessive deposition of extracellular matrix, and gradually develops into diffuse pulmonary fibrosis. Interstitial fibrosis, resulting in pulmonary dysfunction, most patients died of progressive respiratory failure. According to data, unexplained idiopathic pulmonary fibrosis (Idiopathicpulmonary Fibrosis, IPF) accounts for about 60-65% of pulmonary interstitial diseases, is the most common pulmonary interstitial disease, and its 5-year survival rate is lower than 50%, an...

AI Technical Summary

Problems solved by technology

[0003] At present, the clinical treatment of pulmonary interstitial fibrosis mainly adopts hormones, immunosuppressants, cytotoxic drugs (such as thiazolin, cyclophosphamide) and anti-fibrotic agents (such as colchicine, D-cyanine, etc.). Mycamine) alone or in combination, but no matter which treatment method lacks effectiveness and has relatively large side effects

[0004] In addition, some new ideas and treatment methods have emerged for the treatment of pulmonary interstitial fibrosis, such as the use of cytokine inhibitors, anti-adhesion molecule antibodies, anti-C-C chemokines, antioxidants, antagonism of extracellular matrix deposition, Anti-protease, etc., but many of the above methods for treating pulmonary interstitial fibrosis are still in the stage of experimental research or clinical research

So far, there is no drug that can change or reverse the inflammatory process and fibrosis process of pulmonary interstitial fibrosis.

Images